ClinicalTrials.gov
ClinicalTrials.gov Menu

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03041324
Recruitment Status : Recruiting
First Posted : February 2, 2017
Last Update Posted : November 22, 2018
Sponsor:
Information provided by (Responsible Party):
Sangamo Therapeutics

January 13, 2017
February 2, 2017
November 22, 2018
May 11, 2017
February 2021   (Final data collection date for primary outcome measure)
Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to 36 months after the SB-913 infusion ]
Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in subjects who receive SB-913 as assessed by Common Terminology Criteria for Adverse Events (CTCAE)
Treatment related Adverse Events in subjects who received SB-913 as assessed by Common Terminology Criteria for Adverse Events (CTCAE) [ Time Frame: Up to 36 months after the SB-913 infusion ]
Complete list of historical versions of study NCT03041324 on ClinicalTrials.gov Archive Site
  • Effect of SB-913 on IDS activity [ Time Frame: Up to 36 months after the SB-913 infusion ]
    Change from baseline in clinical laboratory measurement of IDS activity measured in plasma.
  • Effect of SB-913 on urine glycosaminoglycans (GAG) levels [ Time Frame: Up to 36 months after the SB-913 infusion ]
    Change from baseline in total GAG, DS GAG, and HS GAG (/creatinine ratio) measured in urine.
  • Annualized frequency of idursulfase (or equivalent ERT) administration. [ Time Frame: Up to 36 months after the SB-913 infusion ]
    Change from baseline in annualized frequency of idursulfase (or equivalent ERT)
  • AAV2/6 clearance in plasma, saliva, urine, stool, and semen [ Time Frame: Up to 36 months after the SB-913 infusion ]
    AAV2/6 clearance by measuring vector genomes in plasma, saliva, urine, stool, and semen by PCR.
  • Change from baseline over time in urine total GAG [ Time Frame: Up to 36 months after the SB-913 infusion ]
  • Change from baseline over time in urine DS GAG [ Time Frame: Up to 36 months after the SB-913 infusion ]
  • Change from baseline over time in urine HS GAG [ Time Frame: Up to 36 months after the SB-913 infusion ]
  • Change from baseline over time in AAV2/6 clearance in plasma [ Time Frame: Up to 36 months after the SB-913 infusion ]
  • Change from baseline over time in AAV2/6 clearance in saliva [ Time Frame: Up to 36 months after the SB-913 infusion ]
  • Change from baseline over time in AAV2/6 clearance in urine [ Time Frame: Up to 36 months after the SB-913 infusion ]
  • Change from baseline over time in AAV2/6 clearance in stool [ Time Frame: Up to 36 months after the SB-913 infusion ]
  • Change from baseline over time in AAV2/6 clearance in semen [ Time Frame: Up to 36 months after the SB-913 infusion ]
Not Provided
Not Provided
 
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II
A Phase I, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)
The purpose of the study is to evaluate the safety, tolerability and effect on leukocyte and plasma Iduronate 2-Sulfatase (IDS) enzyme activity of ascending doses of SB-913. SB-913 is an intravenously delivered Zinc Finger Nuclease (ZFN) Therapeutic for genome editing. It inserts a correct copy of the IDS gene into the Albumin locus in hepatocytes with the goal of lifelong therapeutic production of the IDS enzyme.
The objectives of the study are to provide long term expression of IDS and improve the current clinical outcome of enzyme replacement therapy (ERT) in subjects with MPS II, a recessive lysosomal storage disorder that results from mutations in the gene encoding IDS. SB-913 is a therapeutic for ZFN-mediated genome editing which will be delivered by adeno-associated virus (AAV)-derived vectors. SB-913 is intended to function by placement of the corrective copy of IDS transgene into the genome of the subject's own hepatocytes, under the control of the highly expressed endogenous albumin locus, and is expected to provide permanent, liver-specific expression of Iduronate 2-Sulfatase for the lifetime of an MPS II patient.
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Mucopolysaccharidosis II
  • MPS II
Biological: SB-913
Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor
  • Experimental: Low Dose Group
    Single IV infusion of SB-913
    Intervention: Biological: SB-913
  • Experimental: Medium Dose Group
    Single IV infusion of SB-913
    Intervention: Biological: SB-913
  • Experimental: High Dose Group
    Single IV infusion of SB-913
    Intervention: Biological: SB-913
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
23
9
February 2022
February 2021   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female ≥ 5 years of age
  • Clinical diagnosis of MPS II (based on evidence of hepatosplenomegaly, dysostosis multiplex by X-ray, valvular heart disease, or obstructive airway disease) IDS deficiency confirmed by gene sequencing.

Exclusion Criteria:

  • Known to be unresponsive to ERT
  • Neutralizing antibodies to AAV 2/6
  • Serious intercurrent illness or clinically significant organic disease (unless secondary to MPS II)
  • Receiving antiviral therapy for hepatitis B or C, or with active hepatitis B or hepatitis C or HIV 1/2
  • Lack of tolerance to idursulfase treatment with significant IARs or occurrence of anaphylaxis
  • Markers of hepatic dysfunction
  • Creatinine ≥ 1.5 mg/dL
  • Contraindication to the use of corticosteroids for immunosuppression
  • Current treatment with systemic (IV or oral) immunomodulatory agent or steroid use (topical treatment allowed)
  • Participation in prior investigational drug or medical device study within the previous 3 months
  • Prior treatment with a gene therapy product
  • Elevated or abnormal circulating α-fetoprotein (AFP)
  • Weight < 20 kg at Screening Visit
Sexes Eligible for Study: All
5 Years and older   (Child, Adult, Older Adult)
No
Contact: Medical Monitor send email clinicaltrials@sangamo.com
United States
 
 
NCT03041324
SB-913-1602
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Sangamo Therapeutics
Sangamo Therapeutics
Not Provided
Study Director: Medical Monitor Sangamo Therapeutics
Sangamo Therapeutics
November 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP